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A DNA-mutating enzyme that fine-tunes 
B cell antibody specificity can become a 
dangerous liability if its activity is mistimed, 
misplaced, or left unchecked. Crouch et al. 
(page  1145) have now designed a 
mouse model to track the enzyme’s 
activity in B cells during development 
and immunity. The model can now be 
used to determine how the enzyme’s 
destructive force is controlled.
The enzyme in question is AID 
(activation-induced cytidine deaminase), 
which converts cytidines to uracils. AID 
activity within activated B cells allows 
them to better recognize a pathogen by 
creating mutations in the variable regions 
of their immunoglobulin (Ig) genes. 
AID-assisted recombination within Ig 
constant regions also allows B cells to 
generate different types of antibodies. 
Mismatch repair mechanisms then splice 
out the mutations, reseal the new ends, 
and thereby create new sequence variants 
at the Ig loci. But this AID clean-up 
machinery is itself error-prone and in-
creases the likelihood of further muta-
tions that make the animal vulnerable to 
diseases such as cancer.
To monitor the expression of AID in 
vivo, the team designed transgenic mice 
that express a fluorescent protein upon 
AID activation that then permanently 
marks all AID-expressing cells and their 
progeny. AID, the team found, was not 
expressed by developing B cells. It was 
first switched on in activated B cells that 
were beginning to proliferate in germinal 
centers (GC)—the hub of the B cell 
immune response.
The switch seems to be controlled 
by a short DNA sequence immediately 
downstream of the AID gene. This 
sequence had more histone acetylation 
(which marks transcriptionally active 
regions) in activated B cells. Deleting 
the sequence almost completely abolished 
AID expression.
AID expression was down-regulated 
as B cells differentiated into either 
memory cells or antibody-producing 
plasma cells and began to leave the GC. 
The exact mechanism that shuts off AID 
in exiting B cells remains to be worked 
out. Using this model to resolve this 
mechanism and understand how AID 
regulatory mechanisms get derailed in B 
cell cancers is the team’s next step. 
Keeping track of AID
Avoiding fetal loss
A pregnancy disorder that leads to an early loss of the fetus 
is linked to mutations that increase the mother’s tendency to 
form blood clots. But Sood et al. (page 1049) now find that 
maternal genes are only partly responsible. The rest of the 
blame falls on genetic defects that the fetus inherits from 
the father.
Recurrent miscarriages are associated with mutations 
known as Leiden polymorphisms, which prevent the factor V 
coagulant from being destroyed by the anticoagulation 
machinery. The assumption has been that clots formed in the 
placenta of Leiden mothers might cripple fetal growth by 
blocking nutrient supply.
Examination of placental tissue from Leiden mothers, 
however, shows no correlation between placental clotting 
and fetal loss. And female mice with Leiden mutations give 
birth successfully despite their propensity to form blood clots.
Sood et al. predicted that risk factors from the father 
might increase the risk of fetal loss. They found that crossing 
Leiden female mice with males that had mutations in 
anticoagulation factors now caused the loss of only those 
fetuses that were less able to break down maternal factor V. 
The synergy between maternal and fetal defects suggests 
that screening both parents for anticoagulant mutations may 
be a better indicator of high-risk pregnancies than screening 
only the mother.
The mouse fetal losses were not due to placental clotting, 
but fetal loss was prevented by blocking the activation of the 
mother’s platelets. The authors hypothesize that fetal loss 
must involve an as yet unknown action of maternal platelet 
factors on the fetal cells at the interface of maternal and 
fetal tissue. 
By day 11 of a Leiden pregnancy, a fetus with paternal mutations in 
anticoagulant genes (left) is more decayed than its sibling (right).
Permanently marking B cells that have AID activity with YFP (green) shows that AID is turned on 
upon B cell activation.